FibroScan: Early diagnosis of fibrosis
Liver fibrosis develops when ongoing liver injury leads to the gradual build-up of scar tissue. In its early stages, fibrosis often causes no symptoms. By the time signs such as jaundice, fluid retention or confusion appear, liver disease may already be advanced. This is why early detection is critical.
FibroScan has transformed the way hepatologists assess liver health. It allows for the identification of fibrosis at the right time, often before permanent damage has occurred, and without the need for an invasive biopsy.
What is FibroScan?
FibroScan is a specialised ultrasound-based device that measures liver stiffness using a technology called transient elastography. Increased stiffness usually correlates with fibrosis.
During the test, a probe is placed on the skin over the liver. The machine sends a painless vibration wave through the liver tissue and measures how quickly it travels. The faster the wave moves, the stiffer the liver.
The procedure:
- takes around 10 to 15 minutes;
- is completely non-invasive;
- does not require sedation;
- provides immediate results.
This simplicity makes it suitable for routine monitoring as well as initial assessment.
Why early detection matters
Fibrosis is a progressive process. It can be caused by conditions such as:
- non-alcoholic fatty liver disease;
- alcohol-related liver disease;
- chronic viral hepatitis;
- autoimmune liver conditions.
In the early stages, fibrosis may be reversible if the underlying cause is treated. However, once advanced scarring (cirrhosis) develops, the risk of liver failure and liver cancer increases significantly.
FibroScan enables us to detect fibrosis before patients become symptomatic. Identifying liver stiffness at the right stage allows earlier intervention, whether that involves weight management, antiviral therapy, alcohol reduction or immunosuppressive treatment.
Timing is crucial. Detecting fibrosis too late limits treatment options. Detecting it early can change the long-term outcome.
How advanced is the technology?
FibroScan represents a major advance compared to traditional liver biopsy. While biopsy remains useful in selected cases, it is invasive, carries small procedural risks and samples only a tiny portion of the liver.
In contrast, FibroScan:
- assesses a much larger volume of liver tissue;
- reduces sampling error;
- provides quantitative, reproducible results;
- can be repeated regularly to monitor progression or improvement.
It also includes controlled attenuation parameter (CAP) technology, which measures liver fat content alongside fibrosis. This dual assessment is particularly valuable in metabolic liver disease.
Monitoring disease over time
One of the most important advantages of FibroScan is its ability to track liver stiffness over time. We can assess whether fibrosis is stabilising, improving or progressing, allowing treatment plans to be adjusted promptly.
For patients at risk of chronic liver disease, this ongoing surveillance offers reassurance and objective data.
A tool that changes outcomes
From a hepatology perspective, FibroScan is not simply a diagnostic device. It is a strategic tool that allows fibrosis to be detected at a stage when intervention is most effective.
By combining accuracy, safety and repeatability, this advanced technology plays a central role in preventing progression to cirrhosis and improving long-term liver health.